Deverra Therapeutics, Inc. — Form C-AR (Regulation Crowdfunding)
Deverra Therapeutics, Inc. of Seattle, WA filed a Form C-AR (Regulation Crowdfunding) with the SEC on 2026-05-06.
Offering
- Filed: 2026-05-06
- Form: C-AR
- Accession: 0001822782-26-000003
Issuer
- CIK: 0001822782
- Website: https://www.deverratx.com/
- Legal status: Corporation
- Organized in: DE
- Incorporated: 2020-09-11
- Address: 2033 6th Ave Suite 600, Seattle, WA, 28121
- Employees: 1
Financials (as filed)
- Total assets (most recent): $10.1M
- Cash (most recent): $2K
- Revenue (most recent): $697K
- Revenue (prior): $3.9M
- Net income (most recent): $-1.5M
- Net income (prior): $-3.7M
- Short-term debt: $1.4M
- Long-term debt: $103K
People (5)
| Name | Role | Location |
|---|
| Andrew Albert Kucharchuk | Interim CFO | South San Francisco, CA |
| Colleen Delaney | Scientific Founder and Chief Scientific Officer, EVP of RandD, Director | Wexford, PA |
| Colleen Delaney | Scientific Founder and Chief Scientific Officer, EVP of R&D, Director | Wexford, PA |
| Michael Yurkowsky | CEO | Seattle, WA |
| Michael Yurkowsky | CEO, Director and Chairman | Seattle, WA |
Reg CF filing history (7)
More